SARS-CoV-2 Antibody Test Developed by Promega Receives CE Mark
A SARS-CoV-2 antibody test developed by Promega Corporation, the Lumit Dx SARS-CoV-2 Immunoassay, has received CE marking and is now available in Europe.
- A SARS-CoV-2 antibody test developed by Promega Corporation, the Lumit Dx SARS-CoV-2 Immunoassay, has received CE marking and is now available in Europe.
- The novel bioluminescent immunoassay is a qualitative in vitro diagnostic test intended to detect antibodies to SARS-CoV-2 in serum.
- View the full release here: https://www.businesswire.com/news/home/20210609005062/en/
The Lumit Dx SARS-CoV-2 Immunoassay by Promega has received CE marking. - The novel bioluminescent immunoassay is a qualitative in vitro diagnostic test intended to detect antibodies to SARS-CoV-2 in serum.